Abraxane — Nab-paclitaxel 100 mg, 1 pcs, Bristol-Myers Squibb

Abraxane — nab-Paclitaxel 100 mg Injection Powder, 1 Vial

Product code: 486

19668₴ 21680₴ -9%

Analogues

1
Active ingredient
Dosage form Lyophilisate for infusion
Vials per pack 1
Packaging Glass vial in a box

Abraxane is an advanced antineoplastic agent belonging to the taxane class formulated in an innovative protein-bound nanoparticle delivery system. The active pharmaceutical ingredient is nanoparticle albumin-bound paclitaxel (nab-paclitaxel) at a strength of 100 mg per vial supplied as a lyophilized powder for suspension for intravenous infusion (Paclitaxel albumin-bound 100 mg). The product is developed by Celgene, a subsidiary of the international biopharmaceutical leader Bristol Myers Squibb (BMS).

The primary technological breakthrough of Abraxane is the complete absence of toxic chemical solvents (such as polyoxyethylated castor oil — Cremophor EL and ethanol) required in conventional taxane formulations. Binding paclitaxel to natural human serum albumin forms stable nanoparticles approximately 130 nanometers in size. This formulation facilitates targeted accumulation within tumor tissues utilizing endogenous albumin transport mechanisms across the vascular endothelium (mediated by gp60 and SPARC proteins). Consequently, higher tumor drug delivery is achieved with rapid infusion times while entirely eliminating the requirement for heavy corticosteroid and antihistamine premedication mandatory for standard solvent-based paclitaxel.

Supplied in an outer carton containing 1 glass vial of lyophilized powder (100 mg). Intended exclusively for hospital use under the strict supervision of a qualified oncologist via intravenous infusion.

Key Clinical Features and Advantages of Abraxane 100 mg:

  • ✅ Cremophor-Free Technology: Complete absence of toxic chemical solvents eliminates severe hypersensitivity and anaphylactic reaction risks.
  • ✅ No Heavy Premedication: Does not require mandatory high-dose corticosteroid and antihistamine prophylaxis prior to infusion.
  • ✅ Rapid Infusion Time: Administered as a convenient 30-minute intravenous infusion (compared to 3 hours for standard paclitaxel).
  • ✅ Targeted Nanotransport: Naturally exploits albumin receptors for selective penetration and accumulation within tumor microenvironments.
  • ✅ Original BMS / Celgene Quality: Premium nanotechnology manufacturing standards from the pioneers of albumin-bound drug delivery.

Abraxane is supplied as a lyophilized powder for suspension for intravenous infusion.

Qualitative and Quantitative Composition per Vial:

  • Active Ingredient: Paclitaxel (as albumin-bound nanoparticle particles) — 100 mg.
  • Excipients: Human serum albumin (including sodium caprylate and sodium acetate stabilizers).

Packaging and Presentation: White to yellowish lyophilized powder or cake in a 50 ml colorless glass vial. 1 vial with official prescribing information per outer carton displaying Abraxane (Paclitaxel protein-bound particles for injectable suspension) 100 mg alongside Bristol Myers Squibb / Celgene corporate graphics.

Pharmacodynamics:
Paclitaxel is an antimicrotubule agent that promotes the assembly of tubulin into microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network essential for interphase and mitotic cellular functions, leading to G2/M cell cycle arrest and apoptosis. Additionally, albumin nanoparticles bind to SPARC (secreted protein acidic and rich in cysteine), a protein overexpressed in the stroma of many solid tumors, further increasing intratumoral drug concentrations.

Pharmacokinetics:

  • Distribution: Following intravenous administration, paclitaxel distributes rapidly into body tissues. Plasma protein binding is approximately 89% to 98%. Volume of distribution is high, indicating extensive extravascular tissue uptake.
  • Metabolism: Metabolized primarily in the liver via cytochrome P450 isoenzymes CYP2C8 (yielding 6-alpha-hydroxypaclitaxel) and CYP3A4 (yielding paclitaxel-diketone).
  • Elimination: Excreted predominantly via the fecal biliary route (70% to 90% as metabolites), with less than 6% excreted renally as unchanged drug. Terminal elimination half-life (T1/2) averages 13 to 27 hours.

Abraxane is indicated in adult patients for:

  • Metastatic Breast Cancer: Treatment of metastatic breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy (prior therapy should have included an anthracycline unless clinically contraindicated).
  • Non-Small Cell Lung Cancer (NSCLC): First-line treatment of locally advanced or metastatic NSCLC in combination with carboplatin in patients ineligible for curative surgery or radiation.
  • Metastatic Adenocarcinoma of the Pancreas: First-line treatment of metastatic pancreatic cancer in combination with gemcitabine.

Abraxane is administered strictly as a 30-minute intravenous infusion. Do not use in-line filters with a pore size of less than 15 microns.

Reconstitution Instructions:
Aseptically reconstitute the 100 mg vial by injecting 20 ml of 0.9% Sodium Chloride Injection. Swirl the vial gently for at least 5 minutes until the powder is completely wetted and dissolved. Avoid foaming! The resulting suspension yields a paclitaxel concentration of 5 mg/ml.

Dosing Regimen (by Indication):

  • Breast Cancer: 260 mg/m² body surface area administered intravenously over 30 minutes every 3 weeks.
  • NSCLC: 100 mg/m² on days 1, 8, and 15 of each 21-day cycle in combination with carboplatin.
  • Pancreatic Cancer: 125 mg/m² on days 1, 8, and 15 of each 28-day cycle in combination with gemcitabine.

Administration of Abraxane is contraindicated in:

  • Hypersensitivity: Known hypersensitivity to paclitaxel or human serum albumin.
  • Baseline Myelosuppression: Baseline neutrophil count of less than 1,500 cells/µl.
  • Pregnancy and Lactation: Strictly contraindicated in pregnant or breastfeeding women due to teratogenic and embryotoxic risks.
  • Severe Hepatic Impairment: Pronounced hepatic dysfunction (per specific clinical criteria).

Evaluated drug interactions with Abraxane include:

  • CYP2C8 and CYP3A4 Inhibitors/Inducers (ketoconazole, erythromycin, rifampicin, phenytoin): Because paclitaxel metabolism is mediated by CYP2C8 and CYP3A4, co-administration with potent inhibitors or inducers requires caution.
  • Platinum Compounds (carboplatin, cisplatin): Pharmacokinetics of paclitaxel are unaltered when co-administered with carboplatin.
  • Vaccines: Administration of live or attenuated vaccines during cytotoxic therapy may lead to severe infections.

Pregnancy:
Abraxane is contraindicated during pregnancy due to proven teratogenic, embryotoxic, and mutagenic potential. Women of childbearing potential and male partners must utilize effective contraception during treatment and for several months post-therapy.

Lactation:
Excretion of paclitaxel and its metabolites into human breast milk is unstudied. Breastfeeding must be discontinued during treatment.

The most frequent and clinically significant adverse reactions associated with Abraxane include:

  • Hematologic Toxicity: Neutropenia (often dose-limiting), anemia, thrombocytopenia, febrile neutropenia. Regular complete blood counts are mandatory.
  • Peripheral Neuropathy (Very Common): Sensory neuropathy (numbness, tingling, paresthesias in extremities), typically reversible upon dose reduction or discontinuation.
  • Gastrointestinal Tract: Nausea, vomiting, diarrhea, stomatitis, abdominal pain, decreased appetite.
  • Dermatologic: Alopecia (hair loss occurs in the vast majority of patients), rash, pruritus.
  • General Disorders: Fatigue, asthenia, arthralgia, myalgia, peripheral edema.
  • Cardiovascular System: Blood pressure fluctuations (hypotension or hypertension), sinus bradycardia.

Symptoms:
No specific antidote for paclitaxel overdose is known. Primary overdose manifestations include exacerbation of myelosuppression (severe neutropenia, thrombocytopenia), sensory neuropathy, and pronounced mucositis.

Treatment:
Supportive and symptomatic care should be initiated under close medical supervision, including administration of colony-stimulating factors (G-CSF) and vital organ monitoring.

Storage Requirements for Abraxane 100 mg:

  • 🌡️ Temperature Range: Store in original packaging protected from light at temperatures below 25 °C. Do not freeze!
  • 💧 Reconstituted Suspension: Reconstituted suspensions should be used immediately; however, prepared vials may be stored refrigerated at 2–8 °C for up to 8 hours (protected from light).
  • 👶 Safety Precautions: Keep out of reach of children.
  • ⏳ Shelf Life: Stated on outer carton and vial. Do not use past expiration date. Prescription-only hospital medicine.

To verify authenticity of genuine Abraxane 100 mg manufactured by Bristol Myers Squibb (Celgene), inspect the following features:

  • ✅ Corporate Branding: Distinctive Bristol Myers Squibb corporate logo and Celgene reference printed on the outer carton and vial label.
  • ✅ Packaging Markings: Laser-printed Batch No., manufacturing date, and expiration date matching across carton and vial, displaying Abraxane (Paclitaxel protein-bound particles for injectable suspension) 100 mg.
  • ✅ Vial Presentation: Glass vial sealed with high-grade rubber stopper, aluminum crimp seal, and branded flip-off plastic cap.
  • ✅ Prescribing Information: Includes an official official leaflet inside the outer carton.
100% original product
Delivery across Ukraine
1

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 06.11.2026

Customer reviews

No reviews yet

Your review can be the first!

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00